GT Biopharma Holders Approve 10x Authorized Share Increase to 250 Million
GTBP is trading near its 52-week low of $3.857 (3.7% above the low) on light trading volume (0.4× avg).
Summary
GT Biopharma stockholders approved raising authorized common shares from 25 million to 250 million and cleared the Nasdaq 19.99% issuance cap for its Series M preferred and warrant deal. No shares were issued in this filing; the vote grants capacity for future dilution.
Key Events · Corporate Governance and Compliance · GTBP
-
Authorized Shares Raised 10x
Stockholders approved increasing authorized common stock from 25,000,000 to 250,000,000 shares, with 892,003 votes for, 223,266 against and 31,147 abstaining.
-
Nasdaq 19.99% Issuance Cap Cleared
The Rule 5635 issuance proposal passed 485,607 to 49,077 (9,592 abstentions, 602,140 broker non-votes), permitting issuance of 19.99% or more of outstanding shares on Series M preferred conversion and warrant exercise.
-
No Shares Sold in This Filing
The 8-K reports only vote results; no shares were issued and no proceeds were received. The increase is authorization for future issuance, not completed dilution.
-
Quorum and Record Date
1,146,416 shares, about 55.62% of the 2,061,052 outstanding as of the September 30, 2026 record date, were represented at the November 11, 2026 special meeting.
Analysis · GTBP · Life Sciences
Shareholders have cleared the way for GT Biopharma to issue up to 250,000,000 common shares, ten times the prior 25,000,000 authorization, and separately approved issuing 19.99% or more of the outstanding stock tied to the September 2026 Series M preferred and warrant deal. No shares were sold in this filing — this is permission, not dilution. Yet against 2,061,052 shares outstanding at the September 30 record date, the new authorization leaves enormous headroom that the company can use to convert the Series M preferred, honor warrant exercises, and fund general corporate purposes. For a company that previously disclosed going-concern doubts and Nasdaq minimum-bid risk, that flexibility is the survival mechanism, and the cost is that existing holders face heavy future dilution if the company draws on it.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GTBP was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $3.86 to $28.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.